Tonix Pharm Holdings (TNXP) Stock Price, Quote & News

Company Profile

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company d...

Industry: Biotechnology

Sector: Healthcare

Phone: 862 799 8599

Website: www.tonixpharma.com

Address:

200 Connell Drive, Suite 3100, Berkeley Heights, United States

Stockeye2 Apr. 8 at 10:37 AM

$TNXP 💎

0 · Reply

TokyoCharts Apr. 8 at 9:39 AM

$TNXP $IXHL $USAR $GOVX CC

0 · Reply

ByBi Apr. 8 at 9:33 AM

$TNXP Now that retails capitulated the last few days, the market can move up and never look back before long

0 · Reply

StockJayC Apr. 8 at 9:00 AM

$TNXP New April investor deck https://d1io3yog0oux5.cloudfront.net/_433fd6b9e7afccaa65f314e50f9342d9/tonixpharma/db/211/4548/pdf/TNXP+April+Investor+Deck+FINAL.pdf

1 · Reply

StockJayC Apr. 8 at 8:40 AM

$TNXP 1) Policy Is Shifting the Market Momentum is building behind non-opioid treatments. The Alternatives to PAIN Act aims to improve Medicare Part D access, reducing cost barriers and accelerating adoption. If passed, this directly supports broader uptake of drugs like TONMYA. 2) Precedent Already Exists The NOPAIN Act (active 2025–2027) created separate Medicare reimbursement for non-opioid pain therapies in outpatient settings. While more surgical-focused, it proves policymakers are willing to financially prioritise non-opioids. 3) Regulatory Framework Is Strengthening The SUPPORT Act pushed the FDA to formalise pathways for non-opioid drugs, with new chronic pain guidance now in place. 4) What This Means for TONMYA TONMYA isn’t launching in a vacuum—it’s entering a system actively shifting away from opioids. As legislation, reimbursement, and FDA guidance align, non-opioids are increasingly moving toward preferred access and lower patient cost.

0 · Reply

StockJayC Apr. 8 at 8:34 AM

$TNXP Why the Setup Into Q2 Matters Putting it all together: Q4 = structurally weak launch window Q1 = early signal (still limited by access) Q2 = first quarter where payer expansion + physician familiarity converge With UNH now active and additional insurers likely to follow, we’re moving into the phase where: Access broadens Conversion rates improve Scripts begin to reflect underlying demand rather than access constraints Bottom Line The current numbers don’t yet reflect the real opportunity. What matters now isn’t where TONMYA started—it’s: How quickly coverage expands How fast authorization barriers ease How strongly refill and persistence data trend If those align (as early signs suggest), the next few quarters should give a far more accurate picture of TONMYA’s trajectory. The story is only just beginning.

0 · Reply

StockJayC Apr. 8 at 8:33 AM

$TNXP The “Authorization Bottleneck” – Temporary, Not Structural Right now, prior authorization (PA) is the main friction point. That’s normal for any new branded therapy. However, this phase typically evolves in three steps: Initial friction – heavy PA requirements, limited coverage Data + physician feedback – prescribers build real-world evidence Formulary upgrades – movement to preferred tiers, reduced restrictions We’ve seen this pattern repeatedly across CNS launches. For example: Drugs moving from non-preferred to preferred tiers often see approval rates jump from ~40–50% to 70–90%+ Time-to-fill drops materially, which directly boosts script conversion TONMYA appears to be at the end of phase 1, entering phase 2.

0 · Reply

StockJayC Apr. 8 at 8:33 AM

$TNXP Fibromyalgia Market Dynamics Favour Rapid Uptake TONMYA enters a space that has seen no new drug approvals in ~15 years. Existing options—such as Lyrica, Cymbalta, and Savella—are widely used but often limited by: Tolerability issues Partial efficacy High discontinuation rates Because of this, a large portion of fibromyalgia patients have already cycled through first-line therapies. That’s critical: ➡️ It means many patients can qualify quickly for TONMYA without step therapy delays, especially as payers recognise prior treatment history.

0 · Reply

StockJayC Apr. 8 at 8:32 AM

$TNXP It’s important to recognise just how easy it is to misread the early performance here. The Q4 earnings print showed modest revenue but that was entirely expected given timing. TONMYA was launched into the weakest commercial quarter of the year, when patient activity, prescribing behaviour, and payer movement are all seasonally subdued. The real read-through begins in Q1 and Q2. That’s when we start to see: Normalised prescribing trends Early refill data Initial payer response and access expansion We’ll also have additional script data (thanks to tracking from @JuggernautRaider), which should allow a much clearer estimate of true Q1 revenue contribution from TONMYA—even before full payer activation.

0 · Reply

ThomasH27 Apr. 8 at 7:59 AM

$TNXP 🚀🚀🚀

0 · Reply

Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026

Mar 26, 2026, 7:00 AM EDT - 12 days ago

Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain

Mar 23, 2026, 4:32 PM EDT - 15 days ago

Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026

Mar 18, 2026, 4:58 PM EDT - 20 days ago

Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026

Mar 17, 2026, 4:35 PM EDT - 21 days ago

Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026

Mar 13, 2026, 7:10 AM EDT - 25 days ago

Tonix Pharmaceuticals Says Prescriptions For Chronic Pain Drug Top 4,200 Since Launch

Mar 12, 2026, 5:30 PM EDT - 26 days ago

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Mar 10, 2026, 8:00 AM EDT - 4 weeks ago

Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia

Mar 9, 2026, 4:30 PM EDT - 4 weeks ago

Tonix Pharmaceuticals Presented Data on TONMYA™ in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting

Mar 9, 2026, 4:30 PM EDT - 4 weeks ago

Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting

Mar 5, 2026, 4:15 PM EST - 4 weeks ago

Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development

Mar 3, 2026, 4:30 PM EST - 5 weeks ago

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting

Mar 3, 2026, 7:04 AM EST - 5 weeks ago

Tonix Pharmaceuticals Stock Dips After Nasdaq Uplisting

Mar 3, 2026, 6:00 AM EST - 5 weeks ago

Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market

Feb 25, 2026, 7:00 AM EST - 5 weeks ago

Tonix Pharmaceuticals to Participate in Two Investor Conferences in March

Jan 30, 2026, 7:00 AM EST - 2 months ago

Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

Jan 6, 2026, 7:00 AM EST - 3 months ago

Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026

Dec 29, 2025, 7:57 AM EST - 3 months ago

Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering

Dec 29, 2025, 7:45 AM EST - 3 months ago

Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

Dec 16, 2025, 7:00 AM EST - 4 months ago

Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University

Dec 9, 2025, 7:00 AM EST - 4 months ago

Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel

Nov 24, 2025, 7:00 AM EST - 4 months ago

Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder

Nov 17, 2025, 7:00 AM EST - 5 months ago

Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment

Nov 10, 2025, 4:15 PM EST - 5 months ago

Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights

Nov 6, 2025, 7:00 AM EST - 5 months ago

Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference

Nov 4, 2025, 7:00 AM EST - 5 months ago

Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection

Oct 28, 2025, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025

Oct 27, 2025, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence

Oct 22, 2025, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix's Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital

Oct 21, 2025, 7:00 AM EDT - 6 months ago

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence

Oct 17, 2025, 7:00 AM EDT - 6 months ago

Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025

Oct 14, 2025, 7:00 AM EDT - 6 months ago

Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation

Oct 9, 2025, 7:00 AM EDT - 6 months ago

Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025

Sep 30, 2025, 8:30 AM EDT - 6 months ago

Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access

Sep 29, 2025, 7:00 AM EDT - 6 months ago

Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026

Sep 18, 2025, 8:00 AM EDT - 7 months ago

Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder

Sep 17, 2025, 7:00 AM EDT - 7 months ago

Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

Sep 8, 2025, 7:00 AM EDT - 7 months ago

Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025

Aug 28, 2025, 7:00 AM EDT - 7 months ago

Tonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025

Aug 15, 2025, 3:50 PM EDT - 8 months ago

US FDA approves Tonix Pharma's drug to manage pain related to chronic condition

Aug 15, 2025, 3:44 PM EDT - 8 months ago

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

Aug 11, 2025, 4:15 PM EDT - 8 months ago

Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights

Jul 21, 2025, 7:00 AM EDT - 9 months ago

Tonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia

Jul 10, 2025, 7:00 AM EDT - 9 months ago

Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025

Jul 9, 2025, 4:01 PM EDT - 9 months ago

Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine

Jul 7, 2025, 7:00 AM EDT - 9 months ago

Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025

Jul 2, 2025, 7:00 AM EDT - 9 months ago

Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models

Jun 30, 2025, 7:00 AM EDT - 10 months ago

Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Jun 16, 2025, 7:00 AM EDT - 10 months ago

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025

Jun 13, 2025, 7:00 AM EDT - 10 months ago

Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of Directors

Stockeye2 Apr. 8 at 10:37 AM

$TNXP 💎

0 · Reply

TokyoCharts Apr. 8 at 9:39 AM

$TNXP $IXHL $USAR $GOVX CC

0 · Reply

ByBi Apr. 8 at 9:33 AM

$TNXP Now that retails capitulated the last few days, the market can move up and never look back before long

0 · Reply

StockJayC Apr. 8 at 9:00 AM

$TNXP New April investor deck https://d1io3yog0oux5.cloudfront.net/_433fd6b9e7afccaa65f314e50f9342d9/tonixpharma/db/211/4548/pdf/TNXP+April+Investor+Deck+FINAL.pdf

1 · Reply

StockJayC Apr. 8 at 8:40 AM

0 · Reply

StockJayC Apr. 8 at 8:34 AM

0 · Reply

StockJayC Apr. 8 at 8:33 AM

0 · Reply

StockJayC Apr. 8 at 8:33 AM

0 · Reply

StockJayC Apr. 8 at 8:32 AM

0 · Reply

ThomasH27 Apr. 8 at 7:59 AM

$TNXP 🚀🚀🚀

0 · Reply

Thebigblue Apr. 8 at 7:46 AM

$TNXP

0 · Reply

EquityLabOffice Apr. 8 at 7:39 AM

$TNXP biotech company Tonix Pharmaceuticals.

0 · Reply

Luka_Brasi Apr. 8 at 12:20 AM

$TNXP There's no surer money than shorting this the day of the RS. Many times it dumps hard back to preRS price. Especially if they do a 250:1. Sorry fellas the RS will wipe you out.

0 · Reply

Hoppanin Apr. 7 at 11:40 PM

$TNXP 2-week cease fire. https://www.cnn.com/2026/04/07/world/live-news/iran-war-trump-us-israel

2 · Reply

Innovatenow Apr. 7 at 11:19 PM

$TNXP patience my fellow longs. The setup continues to improve week after week! The launch is gaining traction. More payors are covering Tonmya. More providers understand the advantages of Tonmya. More patients want to try Tonmya. The Q1 and Q2 revenue results will make the progress real for everyone to see; it will establish a higher floor for the stock price. Once Tonix achieves profitability (probably in Q3 or Q4), the stock price will rise dramatically and not look back! The largest gains for investors will materialize for those who choose to hold it over several years as Tonmya gains acceptance as the best treatment for fibromyalgia and other conditions that have a sleep component.

0 · Reply

StavStocks Apr. 7 at 11:04 PM

$TNXP 16 tomorrow

0 · Reply

Pipipopopipi Apr. 7 at 10:07 PM

$TNXP what’s the excuse today you bunch of clowns???

0 · Reply

Pipipopopipi Apr. 7 at 10:05 PM

$TNXP cheer up longs. Seth is preparing another buy around 9-10

0 · Reply

alphonns Apr. 7 at 9:43 PM

$TNXP https://www.barrons.com/market-data/stocks/tnxp/interactive-chart?gaa_n=AWEtsqfl0qWSwmXGRQyg27jC-R8yxS9eoAROknqF7tOP-ipGNx3jBm1aSLr7&gaa_sig=-rTdv8sbLk19AcmWFAYREZpJwMOJfwC06bhSsB8NgnEZr53RYalqiVOFoODzsCmMH8GjiLwyaPR0SJuscrqgbQ%253D%253D

0 · Reply

FrankGelbert Apr. 7 at 8:22 PM

$TNXP Donald! Taco! Taco! Deadline extension! Loosers chickens out! Don't forget!

0 · Reply

FrankGelbert Apr. 7 at 8:17 PM

$TNXP So Donald! Forget TACO! Mullahs power in Hormuz is incredible! TACO! TACO! Oxy alive, Tonix dives! Make Texas great again! Houston, we have no problem! Oxy pumps! Panic arrives!

0 · Reply

FrankGelbert Apr. 7 at 8:06 PM

$TNXP Of course! The only qustion for me is the exact timing for buying Tonix with the last 15% of my bucks! I trust in Seth, his fantastic team and of course Tonmya, by far the best medicine against fibromyalgia! A special tip: have you recogniced, that the molecule behind Tonmya is known for more than 50 years? It is imposible, that there will be unknown bad side effects in some years! That means the lowest possible risk in pharma! I don't like any risk! I am 85% in! Who is more confident? Silence....So, if Donald and panic arrive, Tonix dives! I want to buy it cheap! Dive, baby, dive!

0 · Reply

Market Cap	182.44M
Revenue (ttm)	13.11M
Net Income (ttm)	-124.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-946.00%
Debt to Equity Ratio	0.00

Volume	304,700
Avg Vol	389,874
Day's Range	N/A - N/A
Shares Out	13.41M
Stochastic %K	34%
Beta	1.75
Analysts	Strong Sell
Price Target	$54.33